.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Researchers have recently introduced PathoFact 2.0, a sophisticated bioinformatics pipeline specifically designed for antimicrobial resistance gene prediction. Antimicrobial resistance (AMR) remains a critical threat to global health. Consequently, tools that accurately identify resistance markers are essential for clinical research. PathoFact 2.0 improves upon its predecessor by integrating advanced machine learning models and expanded databases. This tool allows scientists to analyze metagenomic data to pinpoint virulence factors, toxins, and resistance genes simultaneously.
The updated pipeline features a refined machine learning model for identifying virulence factors (VFs). Additionally, it introduces a dedicated model for toxins and toxin-associated proteins. These upgrades ensure higher accuracy and broader coverage than earlier versions. Furthermore, the integration of antiSMASH 7.0 enables the prediction of biosynthetic gene clusters (BGCs). Specifically, this addition helps researchers understand the metabolic potential of microbial communities. By combining these capabilities, PathoFact 2.0 provides a holistic view of microbial pathogenicity.
One of the primary strengths of PathoFact 2.0 is its expanded hidden Markov model (HMM) profiles. These profiles significantly enhance the antimicrobial resistance gene prediction process. Moreover, the tool's compatibility with Linux environments facilitates high-throughput analysis in specialized laboratories. Therefore, clinicians and researchers can better track the spread of drug-resistant pathogens. This comprehensive approach is vital for developing targeted interventions against infectious diseases. Ultimately, PathoFact 2.0 serves as a powerful resource for addressing the complex challenges of AMR.
PathoFact 2.0 is an integrative bioinformatics pipeline used to predict antimicrobial resistance genes, virulence factors, and toxins from metagenomic datasets.
The 2.0 version includes updated machine learning models, expanded HMM profiles, and the integration of antiSMASH 7.0 for predicting biosynthetic gene clusters.
PathoFact 2.0 is developed for and compatible with Linux operating systems.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or professional diagnostic services. Always seek the advice of a qualified healthcare provider regarding any medical condition. Refer to the latest local and national guidelines for clinical practice.
References
Delgado LF et al. PathoFact 2.0: An Integrative Pipeline for the Prediction of Antimicrobial Resistance Genes, Virulence Factors, Toxins and Toxin-associated Proteins, and Biosynthetic Gene Clusters in Metagenomes. Gigascience. 2026 May 22. doi: undefined. PMID: 42172047.
de Nies L et al. PathoFact: a pipeline for the prediction of virulence factors and antimicrobial resistance genes in metagenomic data. Microbiome. 2021 Feb 17;9(1):49. doi: 10.1186/s40168-020-00993-9. PMID: 33597026.
"
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
PathoFact 2.0 is an upgraded pipeline for predicting antimicrobial resistance genes, virulence factors, and toxins using advanced machine learning models....
5 months ago
Discover the crucial role of glymphatic dysfunction in stroke, where perivascular clearance failure and neuroinflammation exacerbate cerebral edema and post-stroke brain injury.
Today
A prenatal case highlights severe glutaric acidemia type II presenting as bilateral hyperechoic cystic kidneys at 18 weeks. Whole-exome sequencing revealed a novel homozygous ETFDH frameshift variant, demonstrating the power of rapid genetic testing in fetal renal anomalies.
Today
Review how tailored exercise programs benefit frail older patients with heart failure. Explore pathophysiological mechanisms, individualized training prescriptions, and strategies to overcome adherence barriers in clinical practice.
Yesterday
This comparative study evaluates posterior labral tears with and without glenohumeral instability, highlighting distinct demographic patterns, MRI underestimation in stable shoulders, and successful arthroscopic repair outcomes.
Yesterday
A clinical study demonstrates that early intervention with tocilizumab, either as monotherapy or bridged with corticosteroids, achieves significant proptosis reduction and resolves active inflammation in treatment-naive thyroid eye disease.
Yesterday
